Omnipod® 5 and CGM Sensor Integrations
How to get the full experience
In order to get all of the advantages of automated insulin delivery (AID) you need a Continuous Glucose Monitor (CGM) sensor. With a CGM sensor connected, your Omnipod 5 can give continuous insulin delivery to help keep you in range, day and night.1-3
Works with the leading CGM sensor brands
Omnipod 5 integrates with Dexcom G7 15 Day for ages 18+ and Dexcom G7 for ages 2+.
NEW! Omnipod 5 now integrates with the FreeStyle Libre 3 Plus sensors and continues to support FreeStyle Libre 2 Plus sensor integration.
For more information visit omnipod.com/compatibility
Dexcom is in the process of discontinuing Dexcom G6 to focus on delivering the next generation of CGM. Omnipod 5 will continue to support integration with Dexcom G6 for as long as this sensor remains available. For more information, please visit www.dexcom.com or contact Dexcom support.
Activate these Omnipod 5 features when you connect a sensor
The Omnipod 5 algorithm
To help correct highs and protect against lows4-6 our algorithm adjusts to your insulin needs every 5 minutes based on readings from your sensor.
SmartBolus Calculator
The SmartBolus Calculator can suggest a bolus dose based on carb amounts and current sensor trend and value, so you don’t have to.
Activity Feature
When enabled, this feature reduces insulin delivery for times when glucose typically goes low, like during exercise.
Looking for more information?
1. Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average day time (6AM-12AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.8% vs. 72.5%; 51.5% vs. 64.6%. Average overnight (12AM-6AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.3% vs. 78.1%; 55.3% vs. 78.1%. Brown et al. Diabetes Care (2021).
2. Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (6AM-12AM) from CGM in standard therapy vs Omnipod 5 = 58.2% vs. 64.3%. Average time in Target Glucose range (12AM-6AM) from CGM in standard therapy vs. Omnipod 5 = 60.6% vs 82.4%. Sherr JL, et al. Diabetes Care (2022).
3. Insulet Data on File. SECURE-T2D Clinical Study Report. 2024. Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean overnight time 70-180 mg/dL (12AM-6AM) as measured by CGM: ST = 49%, 3-mo Omnipod 5 = 70%. Mean daytime 70-180 mg/dL (6AM-12AM) as measured by CGM: ST = 44%, 3-mo Omnipod 5 = 64%. Statistical testing not done to assess significance of change between ST phase and Omnipod 5 System phase.
4. Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average overnight time (12AM-6AM) with high blood glucose in adults/adolescents and children for standard therapy vs Omnipod 5 = 32.1% vs. 20.7%; 42.2% vs. 20.7%. Average day time (6AM-12AM) with high blood glucose in adults/adolescents and children for standard therapy vs Omnipod 5 = 32.6% vs. 26.1%; 46.4% vs. 33.4%. Average overnight time (12AM-6AM) with low blood glucose in adults/adolescents and children for standard therapy vs Omnipod 5 = 3.6% vs. 1.2%; 2.5% vs. 1.2%. Average day time (6AM-12AM) with low blood glucose in adults/adolescents and children for standard therapy vs Omnipod 5 = 2.6% vs. 1.4%; 2.1% vs. 2.0%.
5. Sherr J, et al. Diabetes Care (2022). Study in 80 children with T1D aged 2 to 5.9 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average overnight time (12AM-6AM) with high blood glucose in children for standard therapy vs Omnipod 5 = 38.4% vs. 16.9%. Average day time (6AM-12AM) with high blood glucose in children for standard therapy vs Omnipod 5 = 39.7% vs. 33.7%. Average overnight time (12AM-6AM) with low blood glucose in children for standard therapy vs Omnipod 5 = 3.4% vs. 2.1%. Average day time (6AM-12AM) with low blood glucose in children for standard therapy vs Omnipod 5 = 3.4% vs. 2.6%.
6. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean overnight time >180 mg/dL (12AM-6AM) as measured by CGM: ST = 50%, 3-mo Omnipod 5 = 30%. Mean daytime >180 mg/dL (6AM-12AM) as measured by CGM: ST = 55%, 3-mo Omnipod 5 = 36%. Mean overnight time in <70 mg/dL (12AM-6AM) as measured by CGM: ST = 0.10%, 3-mo Omnipod 5 = 0.22%. Mean daytime <70 mg/dL (6AM-12AM) as measured by CGM: ST = 0.16%, 3-mo Omnipod 5 = 0.17%. Statistical testing not done to assess significance of change between ST phase and Omnipod 5 System phase.
